U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H16Cl2N3O5S.Na.H2O
Molecular Weight 510.323
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DICLOXACILLIN SODIUM

SMILES

O.[Na+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C3=C(C)ON=C3C4=C(Cl)C=CC=C4Cl)C([O-])=O

InChI

InChIKey=SIGZQNJITOWQEF-VICXVTCVSA-M
InChI=1S/C19H17Cl2N3O5S.Na.H2O/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24;;/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28);;1H2/q;+1;/p-1/t13-,14+,17-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H17Cl2N3O5S
Molecular Weight 470.326
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00485 | https://www.ncbi.nlm.nih.gov/pubmed/6559051 | https://www.ncbi.nlm.nih.gov/pubmed/3923593 | https://www.ncbi.nlm.nih.gov/pubmed/20308386

Dicloxacillin sodium USP is a semisynthetic antibiotic substance which resists destruction by the enzyme penicillinase (beta-lactamase). It is monosodium (2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-4- isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2-carboxylate monohydrate. Like other β-lactam antibiotics, dicloxacillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. Dicloxacillin is administered orally via capsule form or powder for reconstitution.

Originator

Sources: Arzneimittel-Forschung Volume14 Issue11 Pages1238-41

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
PATHOCIL

Approved Use

Indications and Usage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules USP and other antibacterial drugs, Dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing). Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin.

Launch Date

1968
Curative
PATHOCIL

Approved Use

Indications and Usage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules USP and other antibacterial drugs, Dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing). Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin.

Launch Date

1968
Curative
PATHOCIL

Approved Use

Indications and Usage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules USP and other antibacterial drugs, Dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing). Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin.

Launch Date

1968
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
45.02 μg/mL
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79.97 μg/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.62 μg/mL
0.25 g single, oral
dose: 0.25 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
24.28 μg/mL
0.5 g single, oral
dose: 0.5 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
110.93 μg × h/mL
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
207.4 μg × h/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
32.78 μg × h/mL
0.25 g single, oral
dose: 0.25 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
62.43 μg × h/mL
0.5 g single, oral
dose: 0.5 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.51 h
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.71 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.38 h
0.25 g single, oral
dose: 0.25 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.44 h
0.5 g single, oral
dose: 0.5 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.7 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICLOXACILLIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
25 mg/kg multiple, oral
Dose: 25 mg/kg
Route: oral
Route: multiple
Dose: 25 mg/kg
Sources:
unhealthy, 2-12
n = 49
Health Status: unhealthy
Condition: skin infection
Age Group: 2-12
Population Size: 49
Sources:
Other AEs: Abdominal pain, Vomiting...
Other AEs:
Abdominal pain (mild, 1 patient)
Vomiting (mild, 1 patient)
Sources:
2 g single, oral
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
healthy, 22.2
n = 16
Health Status: healthy
Age Group: 22.2
Sex: M+F
Population Size: 16
Sources:
0.5 g 4 times / day single, oral
Dose: 0.5 g, 4 times / day
Route: oral
Route: single
Dose: 0.5 g, 4 times / day
Sources:
healthy, 22.3
n = 16
Health Status: healthy
Age Group: 22.3
Sex: M+F
Population Size: 16
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain mild, 1 patient
25 mg/kg multiple, oral
Dose: 25 mg/kg
Route: oral
Route: multiple
Dose: 25 mg/kg
Sources:
unhealthy, 2-12
n = 49
Health Status: unhealthy
Condition: skin infection
Age Group: 2-12
Population Size: 49
Sources:
Vomiting mild, 1 patient
25 mg/kg multiple, oral
Dose: 25 mg/kg
Route: oral
Route: multiple
Dose: 25 mg/kg
Sources:
unhealthy, 2-12
n = 49
Health Status: unhealthy
Condition: skin infection
Age Group: 2-12
Population Size: 49
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: ketoconazole decreased flux of dicloxacillin
Page: 457.0
PubMed

PubMed

TitleDatePubMed
Clinical, laboratory, and pharmacological studies of dicloxacillin.
1966
Compatibility between active components of a commercial drug.
2002 Oct
Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment.
2003
Dicloxacillin: a higher risk than cloxacillin for infusion phlebitis.
2003
Confirmatory analysis of beta-lactam antibiotics in kidney tissue by liquid chromatography/electrospray ionization selective reaction monitoring ion trap tandem mass spectrometry.
2003
[Long-term antibiotic suppressive therapy for an infected thoracic aorta graft].
2003 Aug 28
Residues of beta-lactam antibiotics in bovine milk: confirmatory analysis by liquid chromatography tandem mass spectrometry after microbial assay screening.
2003 Jun
[Treatment of mastitis in general practice].
2003 Nov 6
Large-volume sample stacking combined with separation by 2-hydroxypropyl-beta-cyclodextrin for analysis of isoxyzolylpenicillins by capillary electrophoresis.
2003 Sep
Necrotizing surgical site infection after tension-free vaginal tape.
2004 Dec
Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
2004 Feb 19
Application of ion-exchange cartridge clean-up in food analysis. VI. Determination of six penicillins in bovine tissues by liquid chromatography-electrospray ionization tandem mass spectrometry.
2004 Jul 9
Community-acquired methicillin-resistant Staphylococcus aureus among military recruits.
2004 May
Interaction of dicloxacillin with warfarin.
2004 May
Cases from the aerospace medicine residents' teaching file: furunculosis.
2004 Nov
Interactions of two amphiphilic penicillins with myoglobin in aqueous buffered solutions: a thermodynamic and spectroscopy study.
2004 Nov-Dec
Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002.
2004 Sep
Laser-mediated photodynamic therapy of actinic cheilitis.
2004 Sep-Oct
Biodegradable polymer releasing antibiotic developed for drainage catheter of cerebrospinal fluid: in vitro results.
2005 Apr
Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics.
2005 Apr
Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry.
2005 Aug
Catheter-related septic thrombophlebitis of the great central veins successfully treated with low-dose streptokinase thrombolysis and antimicrobials.
2005 Aug 22
Development of a novel and automated fluorescent immunoassay for the analysis of beta-lactam antibiotics.
2005 Aug 24
Diagnosis and management of staphylococcal infections of vascular grafts and stents.
2005 Dec
Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators.
2005 Dec
Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus.
2005 Dec
Thermodynamic study of the effect of ethanol on two amphiphilic penicillins.
2005 Dec 1
[Treatment of chronic bovine endometritis and factors for treatment success].
2005 Jan
Local gentamicin reduces sternal wound infections after cardiac surgery: a randomized controlled trial.
2005 Jan
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
2005 Jan
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.
2005 Jul
Methicillin-resistant Staphylococcus aureus in community-acquired skin infections.
2005 Jun
The relationship between inhibition of bacterial adhesion to a solid surface by sub-MICs of antibiotics and subsequent development of a biofilm.
2005 Jun-Jul
Confirmatory and quantitative analysis of beta-lactam antibiotics in bovine kidney tissue by dispersive solid-phase extraction and liquid chromatography-tandem mass spectrometry.
2005 Mar 1
Influence of sub-inhibitory concentrations of antimicrobial agents on biofilm formation in indwelling medical devices.
2005 Nov
Cheilitis glandularis in an African-American woman: response to antibiotic therapy.
2005 Nov-Dec
Clonal spread of Staphylococcus aureus with reduced susceptibility to oxacillin in a dermatological hospital unit.
2006
Influence of SDS and two anionic hydrotropes on the micellized state of the triblock copolymer E71G7E71.
2006 Apr 15
Positive effect of natural and negatively charged cyclodextrins on the stabilization of penicillins towards beta-lactamase degradation due to inclusion and external guest-host association. An NMR and MS study.
2006 Apr 7
Recurrent staphylococcal conjunctivitis associated with facial impetigo contagiosa.
2006 Jan
Efficient approach for the reliable quantification and confirmation of antibiotics in water using on-line solid-phase extraction liquid chromatography/tandem mass spectrometry.
2006 Jan 20
Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.
2006 Jan 6
Molecular engineering of fluorescent penicillins for molecularly imprinted polymer assays.
2006 Mar 15
Spectrophotometric determination of flucloxacillin and dicloxacillin in pure and dosage forms.
2006 May 1
In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.
2006 Oct 12
Determination of antimicrobials in sludge from infiltration basins at two artificial recharge plants by pressurized liquid extraction-liquid chromatography-tandem mass spectrometry.
2006 Oct 13
Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients.
2006 Sep 11
Analysis of different beta-lactams antibiotics in pharmaceutical preparations using micellar electrokinetic capillary chromatography.
2007 Jan 17
Heterogeneity of human adipose blood flow.
2007 Jan 20
Oral beta-lactams applied to uncomplicated infections of skin and skin structures.
2007 Mar
Patents

Sample Use Guides

Usual Adult Dose for Bronchitis: 250 to 500 mg orally every 6 hours for 10 days, depending on the nature and severity of the infection. Usual Adult Dose for Pneumonia: 500 mg orally every 6 hours for up to 21 days, depending on the nature and severity of the infection.
Route of Administration: Oral
Bacteria strains ATCC 25923 and E19977 at a density of 10-6 Colony-forming unit /ml were exposed to Dicloxacillin concentrations that varied over a wide range (to obtain a full description of the pharmacological response), and quantification of the numbers of Colony-forming unit was performed after 5 and 24 h of incubation. The MICs of Dicloxacillin at pH 7.4 was 0.125 mg/liter (ATCC 25923) and 0.5 mg/liter (E19977).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:23:06 GMT 2023
Edited
by admin
on Fri Dec 15 15:23:06 GMT 2023
Record UNII
4HZT2V9KX0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DICLOXACILLIN SODIUM
EP   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-IP  
USAN  
Official Name English
DICLOXACILLINUM NATRICUM [WHO-IP LATIN]
Common Name English
P-1011
Code English
DICLOXACILLIN SODIUM [USP-RS]
Common Name English
DICLOXACILLIN SODIUM [ORANGE BOOK]
Common Name English
DICLOXACILLIN SODIUM [VANDF]
Common Name English
DICLOXACILLIN SODIUM SALT MONOHYDRATE
MI  
Common Name English
SODIUM DICLOXACILLIN MONOHYDRATE
Common Name English
NSC-756726
Code English
DICLOXACILLIN SODIUM [USP IMPURITY]
Common Name English
DICLOXACILLIN SODIUM [WHO-IP]
Common Name English
DICLOXACILLIN SODIUM HYDRATE [JAN]
Common Name English
DICLOXACILLIN SODIUM [USAN]
Common Name English
DICLOXACILLIN SODIUM SALT MONOHYDRATE [MI]
Common Name English
DICLOXACILLIN SODIUM MONOHYDRATE
GREEN BOOK   WHO-DD  
Common Name English
DYNAPEN
Brand Name English
DYCILL
Brand Name English
Monosodium (2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate monohydrate
Systematic Name English
DICLOXACILLIN SODIUM [MART.]
Common Name English
DICLOXACILLIN SODIUM MONOHYDRATE [GREEN BOOK]
Common Name English
SODIUM DICLOXACILLIN
Common Name English
DICLOXACILLIN SODIUM [USP MONOGRAPH]
Common Name English
Dicloxacillin sodium monohydrate [WHO-DD]
Common Name English
DICLOXACILLIN SODIUM [EP MONOGRAPH]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-(((3-(2,6-DICHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL)CARBONYL)AMINO)-3,3-DIMETHYL-7-OXO-, MONOSODIUM SALT, MONOHYDRATE, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.))-
Common Name English
PATHOCIL
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
Code System Code Type Description
CHEBI
52019
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
CAS
13412-64-1
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
NSC
756726
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
EVMPD
SUB11900MIG
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
DRUG BANK
DBSALT001622
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
PUBCHEM
23675786
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
RS_ITEM_NUM
1189009
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
RXCUI
267257
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
DICLOXACILLIN SODIUM
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder.Solubility: Freely soluble in water and methanol R; soluble in ethanol (~750 g/l) TS.Category: Antibacterial drug.Storage: Dicloxacillin sodium should be kept in a tightly closed container, protected from light.Additional information: Even in the absence of light, Dicloxacillin sodium is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures.Definition: Dicloxacillin sodium contains not less than 88.0% of total penicillins calculated as dicloxacillin free acid (C19H17Cl2N3O5S) and with reference to the anhydrous substance.
CHEBI
34691
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
EPA CompTox
DTXSID2049002
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
FDA UNII
4HZT2V9KX0
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
ChEMBL
CHEMBL893
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
DAILYMED
4HZT2V9KX0
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
SMS_ID
100000087924
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
WIKIPEDIA
Dicloxacillin sodium
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
EVMPD
SUB01675MIG
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
MERCK INDEX
m4364
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C47985
Created by admin on Fri Dec 15 15:23:06 GMT 2023 , Edited by admin on Fri Dec 15 15:23:06 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY